摘要
目的观察艾塞那肽对高海拔地区T2DM伴多囊卵巢综合征(PCOS)患者的疗效和安全性。方法选取于我科住院的来自高海拔地区T2DM伴PCOS患者75例,随机分为对照(Con)组和艾塞那肽组,Con组口服二甲双胍500mg,3次/d,艾塞那肽组予艾塞那肽5μg,早、晚餐前1h皮下注射,治疗1个月后改为10μg,早、晚餐前1h皮下注射,治疗3个月。测定治疗前后FPG、FIns、2hPG、2hIns、HbA_1c、体重、血脂、性激素等,计算BMI及胰岛素抵抗指数(HOMA-IR)。记录用药期间低血糖发生情况和其他不良反应。结果治疗后两组BMI、HbA_1c、FPG、2hPG、TG、TC、LDL-C、FIns和HOMA-IR较治疗前降低,且艾塞那肽组低于Con组(P<0.05)。治疗后两组血清促黄体生成素(LH)及睾酮(T)较治疗前降低(P<0.05)。均无低血糖及严重不良反应发生。结论艾塞那肽能有效控制高原地区T2DM伴PCOS患者血糖,降低BMI、改善血脂水平、IR和高雄激素血症。
Objective To investigate the efficacy and safety of Exenatide in patients type 2diabetes（T2DM）and polycystic ovary syndrome（PCOS）in plateau area. Methods A total of 75 T2 DM patients with PCOS from plateau area admitted in our hospital were enrolled in this study and divided into two groups：control group（Con）and Exenatide treatment group.The Con group was treated with Metformin 500 mg,3/d,and the Exenatide treatment group was given subcutaneous injection of Exenatide5μg,1hbefore breakfast and dinner,and increased to 10μg one month later,and followed up for three months.FPG,FIns,2hPG,2hIns,HbA1 c,body weight,blood lipid,and sex hormones were tested at baseline and after treatment.BMI and insulin resistance index（HOMA-IR）were also calculated.Hypoglycemia and other adverse events during follow up were recorded. Results BMI,HbA1 c,FPG,2hPG,TG,TC,LDL-C and HOMA-IR were decreased after treatment,and all these above indexes were lower in Exenatide treatment group than in Con group（P〈0.05）.Serum luteinizing hormone（LH）and testosterone（T）were decreased after treatment（P〈0.05）.There were no hypoglycemia or other severe adverse events in either groups. Conclusion Exenatide can effectively control blood glucose in patients with T2 DM and PCOS in plateau area,and also lower BMI,improve blood lipid and hyperandrogenemia.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2017年第3期241-244,共4页
Chinese Journal of Diabetes
基金
吴阶平医学基金(320-6750-15199)
关键词
艾塞那肽
高海拔
多囊卵巢综合征
糖尿病
2型
Exenatide
High altitude
Polycystic ovary syndrome（PCOS）
Diabetes mellitus,type 2
